Cigarette smoking may selectively enhance VSWM and attentional deficits in smokers with schizophrenia, which may depend on nAChR stimulation. These findings may have implications for understanding the high rates of smoking in schizophrenia and for developing pharmacotherapies for cognitive deficits and nicotine dependence in schizophrenia.

Background-Schizophrenics smoke at higher rates (58-88%) than the general population (~22%), and have great difficulty with quitting smoking. We determined if the combination of sustainedrelease (SR) bupropion (BUP) with transdermal nicotine patch (TNP) is well-tolerated, and superior to placebo (PLO) + TNP for smoking cessation in schizophrenia.

No abstract

No abstract